coli) (MLH1), (4) DNA mismatch repair
protein Msh2 (MSH2), mutS homolog 6 (MSH6), mismatch repair endonuclease PMS2 (PMS2), and epithelial cell adhesion molecule (EPCAM), such as occurs in patients with Lynch syndrome, for whom more than 90% of colon cancers test MSI positive (1, 2).
Microsatellites are short repetitive sequences of DNA; MSI, which is detected by polymerase chain reaction (PCR)-based assays that reveal the mutated microsatellites, results from impaired DNA mismatch repair
Another autosomal-dominant disorder, hereditary nonpolyposis colorecstal cancer (HNPCC) syndrome arises as a result of a genetic defect in DNA mismatch repair
Moreover, it has been suggested that UEC may be linked to the group of tumors belonging to hereditary nonpolyposis colorectal carcinoma or Lynch syndrome, since a significant percentage of cases display loss of 1 or more of the DNA mismatch repair
DNA mismatch repair
proteins including MLH1, MSH2, MSH6 and PMS2 were all intact by immunohistochemistry.
The autosomal dominant disorder is caused by a mutation in one of four DNA mismatch repair
(MMR) genes: MLH1, MSH2, MSH6, or PMS2.
HNPCC is associated with germ-line mutations in DNA mismatch repair
(MMR) genes namely MLH1, MSH2, MSH6, and PMS2 (4-7).
5) MSI is associated with mutations in the DNA mismatch repair
genes hMLH1 and hMSH2, and less frequently hMSH6 and PMS2, leading to the rapid development of neoplasms through the accumulation of mutations.
Cd(II) was recently shown to inhibit DNA mismatch repair
(MMR) (Jin et al.
25,26) Farrington et al (24) suggested that it is necessary to analyze DNA mismatch repair
genes regardless of the family history, especially in early onset CRC.
One of the two non-resistant lines and its resistant clone were deficient in their DNA mismatch repair
systems, which results in genetic instability, increased susceptibility to neoplastic transformation, and greater development of chemoresistant cells.
Selection of endometrial carcinomas for DNA mismatch repair
protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.